WHO ICTRP trial
Randomized prospectic clinical trial Phase II in patients affected by prognostic…
EUCTR2009-016813-11-IT · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2009-016813-11-IT |
|---|---|
| Public title | Randomized prospectic clinical trial Phase II in patients affected by prognostic class RPA V and VI glioblastoma: comparison between hypofractionated radiotherapy (RT) 30 Gy (6 fractions in two weeks) and esclusive temozolomide (TMZ)(200 mg/m2 for 5 days every 28) - AOBS-RT-TMZ |
| Scientific title | Randomized prospectic clinical trial Phase II in patients affected by prognostic class RPA V and VI glioblastoma: comparison between hypofractionated radiotherapy (RT) 30 Gy (6 fractions in two weeks) and esclusive temozolomide (TMZ)(200 mg/m2 for 5 days every 28) - AOBS-RT-TMZ |
| Primary sponsor | AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Italy |
| Conditions | Patients with histological diagnosis od glioblastoma in RPA class V and VI and age =>65 yrs. MedDRA version: 9.1 Level: SOC Classification code 10029104 |
| Interventions | Pharmaceutical Form: Capsule, hard INN or Proposed INN: Temozolomide Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- |
| Registration date | Apr 1, 2010 |
| Secondary IDs | AOBS-RT-TMZ |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: